HeartFlow, Inc. (NASDAQ: HTFL) disclosed that Director Jeffrey C. Lightcap purchased 47,420 shares of common stock on July 24, 2026, at $19 per share, according to a regulatory filing released July 28, 2026. The transaction brings Lightcap's direct beneficial ownership to 293,681 shares. Lightcap, who holds controlling interests in two investment funds that also maintain significant stakes in HeartFlow, demonstrated continued confidence in the company through this open-market purchase.
Key Points
- NASDAQ: HTFL
- Director Jeffrey C. Lightcap acquired 47,420 common shares at $19 per share on July 24, 2026
- Transaction increased Lightcap's direct ownership to 293,681 shares; he indirectly controls approximately 6.7 million additional shares through affiliated funds
- Lightcap serves as a controlling member of HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P., which collectively hold 5,864,481 shares
Director's Direct Share Purchase and Current Holdings
Jeffrey C. Lightcap, listed as a director of HeartFlow, Inc., acquired 47,420 shares of common stock in a market transaction executed on July 24, 2026. The filing states that Lightcap purchased these shares at a price of $19 per share, representing a total investment value of approximately $900,980 based on the disclosed transaction price. Following the completion of this transaction, Lightcap's direct beneficial ownership of HeartFlow common stock increased to 293,681 shares, all held in direct form rather than through intermediary entities.
The purchase represents a notable insider commitment to the company and suggests confidence in HeartFlow's business trajectory by a member of the board of directors. Direct purchases by company insiders at market prices are often monitored by investors and analysts as potential indicators of management's assessment of company value. The transaction was reported through standard SEC Form 4 procedures, which require directors, officers, and substantial shareholders to disclose changes in beneficial ownership within two business days of the transaction date.
Substantial Indirect Ownership Through Investment Partnerships
In addition to his direct shareholding, Lightcap maintains significant indirect beneficial ownership stakes in HeartFlow through his controlling positions in two investment funds. The disclosure reveals that Lightcap is the controlling member of HCPCIV 1, LLC, which beneficially owns 4,615,542 shares of HeartFlow common stock. This represents the largest single block of shares attributed to Lightcap's sphere of control and underscores his substantial influence within the shareholder base.
Beyond the LLC structure, Lightcap also holds controlling membership interests in two limited partnership vehicles. HealthCor Partners Fund II, L.P. maintains beneficial ownership of 833,075 HeartFlow shares, while HealthCor Partners Fund, L.P. holds an additional 1,248,939 shares. The filing clarifies that Lightcap, as a controlling member of both partnerships, may be deemed to possess voting and dispositive power with respect to these holdings. Combined with his direct ownership, these indirect positions represent approximately 6.7 million shares of beneficial interest, establishing Lightcap as a major shareholder in the medical imaging technology company.
Disclaimer of Full Beneficial Ownership for Affiliated Entities
The filing includes an important clarification regarding Lightcap's relationship to shares held by his affiliated investment entities. Lightcap expressly disclaims beneficial ownership of the securities held through HCPCIV 1, LLC and the HealthCor Partners funds except to the extent of his pecuniary interest therein. This disclaimer is a standard provision in insider trading disclosures and reflects securities law conventions regarding indirect ownership structures. The inclusion of these shares in the Form 4 report does not constitute an admission of beneficial ownership for purposes of Section 16 of the Securities Exchange Act or any other regulatory purpose beyond the reporting requirements themselves.
This distinction between controlling power and beneficial ownership ownership is important for investors to understand. While Lightcap may exercise voting and dispositive authority over the shares held in partnership and LLC structures due to his controlling member status, the funds themselves and their other stakeholders retain distinct ownership interests. The disclaimer ensures compliance with SEC regulations while maintaining transparency regarding Lightcap's connected financial interests in HeartFlow's equity performance and strategic direction.
Stock Option Grants and Exercise Arrangements
In addition to the common stock acquisition, the disclosure reveals that Lightcap received a grant of stock options as part of his compensation or incentive arrangement as a director. The filing indicates that 47,420 stock options were granted on July 24, 2026, the same date as the common stock purchase. These options carry an exercise price of $19 per share, matching the price at which Lightcap purchased the concurrent common shares, and are described as fully exercisable, meaning there are no remaining vesting restrictions limiting Lightcap's ability to exercise them immediately.
The options expire on August 7, 2035, providing a nine-year window during which Lightcap may exercise the right to purchase an additional 47,420 shares of HeartFlow common stock at the fixed $19 strike price. Should HeartFlow's stock price appreciate meaningfully above this level during the option period, these instruments could represent significant additional value to Lightcap. The simultaneous grant of options and direct share purchase on the same date suggests a coordinated equity compensation or incentive event, possibly related to board service, option pool replenishment, or strategic realignment of management incentives at the company.
Reporting Person Status and Section 16 Obligations
The Form 4 filing confirms that Jeffrey C. Lightcap is classified as a director of HeartFlow, Inc., which automatically subjects him to Section 16 reporting obligations under the Securities Exchange Act of 1934. Section 16 requires directors, certain officers, and beneficial owners of more than ten percent of a company's equity securities to file disclosure statements whenever their beneficial ownership changes. Lightcap's position as a director triggers these mandatory reporting requirements regardless of the size of his shareholding, ensuring that all material changes in his equity stake are disclosed to the investing public within the prescribed timeframe.
The filing was signed on July 28, 2026, which represents the standard two-business-day reporting window from the July 24, 2026 transaction date. HeartFlow's company address is listed as 135 Main Street, Suite 1000, San Francisco, California 94105. The disclosure was executed by Nga Van acting by power of attorney on behalf of Lightcap, a common procedural mechanism for ensuring timely filing of insider trading reports. The attestation language in the form emphasizes that intentional misstatements or omissions of material facts in the filing constitute federal criminal violations under 18 U.S.C. Section 1001 and securities fraud provisions, underscoring the legal seriousness of these disclosures.
Implications for HeartFlow's Shareholder Structure
The transaction and resulting beneficial ownership positions reveal that Lightcap and his affiliated entities collectively represent one of the most substantial shareholder blocs within HeartFlow. With approximately 6.7 million shares of beneficial interest across direct and indirect holdings, Lightcap's voting power and economic stake in the company's performance position him as a key stakeholder influencing corporate governance and strategic decisions. His continued investment through the July 2026 share purchase suggests ongoing alignment between his financial interests and the company's growth prospects.
For investors monitoring HeartFlow's shareholder base and insider activity, Lightcap's purchase at $19 per share and the concurrent option grant may signal board-level views regarding the company's valuation and growth potential. Insider purchases are frequently analyzed by market participants as potential indicators of management confidence, though such transactions can reflect various motivations including compensation structure, tax planning, or diversification strategies unrelated to near-term outlook. The scale of Lightcap's existing stakes through the investment partnerships, combined with his new direct acquisition, demonstrates sustained commitment to HeartFlow's equity by a member of the board responsible for oversight of management and company strategy.
Transaction Mechanics and Securities Law Compliance
The acquisition of 47,420 common shares at $19 per share represents an open-market transaction, meaning the shares were purchased through normal trading channels rather than through a private placement, restricted offering, or company-facilitated program. The transaction code used in the filing identifies this as a regular market purchase, distinguishing it from option exercises, inheritance transfers, or other non-market mechanisms of share acquisition. The price of $19 aligns with HeartFlow's trading patterns around late July 2026, reflecting prevailing market valuations at the time of execution.
The filing does not indicate that this transaction was made pursuant to a Rule 10b5-1 trading plan, which is a pre-arranged program allowing insiders to purchase or sell securities according to predetermined schedules without violating insider trading prohibitions. The absence of such a designation suggests that this purchase was executed as a discretionary open-market transaction by Lightcap or his representatives. All share quantities, prices, and dates disclosed in the Form 4 filing represent the factual record as reported to the SEC and constitute the official documentation of this insider transaction for regulatory and public disclosure purposes.



Please wait processing your request...